Effortless

Gaudium IVF and Women Health, India’s first dedicated fertility‑care platform to list on the mainboard, is already drawing a cluster of serious HNI and fund money into its small float. In less than a week after listing, three well‑tracked names — Param Capital, GDN Investments and Kishan Gopal Mohta — have together cornered over 50 lakh shares via bulk deals, effectively anchoring a big slice of the available paper.

What makes Gaudium different

Gaudium is not a generic hospital stock; it is a focused IVF and fertility‑care chain.

• Pure fertility‑care play: It operates IVF, ICSI, IUI and related ART procedures across a pan‑India network.
• Hub‑and‑spoke model: 7 high‑end IVF hubs plus 28 spokes at 30‑plus locations, designed to push specialised IVF into tier‑2 and tier‑3 markets.
• Scarcity value: There are no other pure IVF/fertility mainboard peers in India; most listed healthcare names are hospitals, diagnostics or broader multi‑speciality chains.

The IPO itself was structured to fund exactly this IVF rollout — ₹50 crore earmarked for 19 new centres, largely in underpenetrated cities, with another ₹20 crore for debt repayment. That combination of niche, high‑margin healthcare + visible expansion capex is precisely the template HNI stock‑pickers look for.

The bulk‑deal tape: who bought and who sold

The early flows tell a neat story of “AIFs out, stock‑pickers in.”

Listing day (27 Feb 2026): AIF profit‑taking into Param and GDN

On 27 February, the day Gaudium listed:

• Sellers:
  • Minerva Emerging Opportunities Fund Limited – 10,00,000 shares @ ₹83 (sell).
  • Neomile India Opportunity Fund – 15,76,910 shares @ ₹84.89 (sell).
• Buyers:
  • Param Capital – 25,00,000 shares @ ₹85.51 (buy).
  • GDN Investments Pvt Ltd – 20,00,000 shares @ ₹83.30 (buy).

Day 3 (2 Mar 2026): Kishan Gopal Mohta joins the cap table

Within three trading days, another name appears:

• 2 March – Kishan Gopal Mohta buys 7,00,000 shares @ ₹82.01 (bulk buy, NSE).

Why these three buyers matter

Param Capital (Mukul Agrawal)

Param Capital is widely recognised as Mukul Agrawal’s investing vehicle, known for early, high‑conviction stakes in small and mid‑caps that often later institutionalise. A 25 lakh‑share buy in a just‑listed IVF name signals that Gaudium has passed that “owner‑operator, scalable niche, decent valuations” filter.

GDN Investments Pvt Ltd

GDN is not a broker front; it repeatedly shows up alongside marquee HNIs in SME and mid‑cap bulk deals as a family‑office style investor. Its 20 lakh‑share position in Gaudium, at close to Param’s price, effectively doubles down on the same thesis — and concentrates more of the float with aligned investors rather than fast money.

Kishan Gopal Mohta

Mohta’s 7 lakh‑share purchase at ₹82 comes after the initial listing volatility has played out, and slightly below Param’s blended price. For tape‑readers, that looks like a reinforcing signal: another stock‑picker with a documented bulk‑deal track record is willing to come in size once the listing dust settles.

Post‑listing setup

On fundamentals, Gaudium screens as a high-margin, IVF-focused healthcare platform with IPO-funded expansion and no direct listed pure-play peer. On ownership, promoters already hold about 71% post-issue, which means the effective free float is limited even before counting anchor investors and early secondary buyers. Against that tight float, the first big post-listing rotation is already visible: AIFs like Minerva and Neomile have partly sold, while Param Capital, GDN Investments and Kishan Gopal Mohta have absorbed a meaningful chunk of the available paper, turning Gaudium into a clear “smart-money in IVF” story to track over the next few quarters.